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Background: Dopamine has been used in patients with cardiac dysfunction for more
than five decades. Yet, no systematic review has assessed the effects of dopamine
in critically ill patients with cardiac dysfunction.
Methods: This systematic review was conducted following The Cochrane Handbook
for Systematic Reviews of Interventions. We searched for trials including patients
with observed cardiac dysfunction published until 19 April 2018. Risk of bias was
evaluated and Trial Sequential Analyses were conducted. The primary outcome was
all‐cause mortality at longest follow‐up. Secondary outcomes were serious adverse
events, myocardial infarction, arrhythmias, and renal replacement therapy. We used
GRADE to assess the certainty of the evidence.
Results: We identified 17 trials randomising 1218 participants. All trials were at
high risk of bias and only one trial used placebo. Dopamine compared with any con-
trol treatment was not significantly associated with relative risk of mortality (60/457
[13%] vs 90/581 [15%]; RR 0.91; 95% confidence interval 0.68‐1.21) or any other
patient‐centred outcomes. Trial Sequential Analyses of all outcomes showed that
there was insufficient information to confirm or reject our anticipated intervention
effects. There were also no statistically significant associations for any of the out-
comes in subgroup analyses by type of comparator (inactive compared to potentially
active), dopamine dose (low compared to moderate dose), or setting (cardiac surgery
compared to heart failure).
Conclusion: Evidence for dopamine in critically ill patients with cardiac dysfunction
is sparse, of low quality, and inconclusive. The use of dopamine for cardiac dysfunc-
tion can neither be recommended nor refuted.
1 | INTRODUCTION
Dopamine is a natural catecholamine which has various cardiovascular
effects throughout a dose‐dependent activation of dopaminergic, α‐PROSPERO registration number: CRD42016042867
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and β‐adrenergic receptors.1 Low‐dose dopamine (<4 µg·kg−1·min−1)
is hypothesised to primarily provide mesenteric and renal arteriole
vasodilation, moderate‐dose dopamine (4‐10 µg·kg−1·min−1) is hypoth-
esised to have particularly positive inotropic and chronotropic effects,
and high‐dose dopamine (>10 µg·kg−1·min−1) is considered a vaso-
pressor due to the increase of systemic vascular resistance.1,2 These
doses are arbitrary as there is a wide interindividual variability of
dopamine receptor sensitivity.2
Guidelines for treatment of heart failure mention dopamine
among other drugs to treat acute heart failure.3,4 Several randomised
clinical trials (RCTs) have failed to show clinical benefits associated
with use of dopamine in patients with acute heart failure5‐7 and cir-
culatory shock.8 Previous meta‐analyses advocate cautious use of
high‐dose dopamine.9 Despite the decline in its use, dopamine is still
the used inotrope in 25% of acute heart failure patients and in 14%
of the patients undergoing cardiac surgery.10,11
The debate about the benefits and harms of dopamine in critically
ill patients with cardiac dysfunction remains.11,12 Our objective was to
conduct a systematic review with meta‐analyses and Trial Sequential
Analyses (TSA) of RCTs comparing the benefits and harms of dopa-
mine compared to placebo, no intervention, or any potentially active
comparator in critically ill patients with cardiac dysfunction.
2 | METHODS
This systematic review was conducted following our published pro-
tocol (CRD42016042867),13 the recommendations of The Cochrane
Handbook for Systematic Reviews of Interventions,14 The Cochrane
Hepato‐Biliary Group Module,15 and was reported according to the
Preferred Reporting Items for Systematic Reviews and Meta‐Analy-
ses (PRISMA) statement.16
2.1 | Eligibility criteria
We considered all RCTs eligible for inclusion irrespective of lan-
guage, blinding, publication status, sample size, or control interven-
tion(s) for assessment of benefits and harms. Quasi‐randomised and
observational studies were included for assessment of potential
harms and results were analysed separately.
Only RCTs with critically ill adult patients with cardiac dysfunc-
tion were included in our main analysis. Critical illness encompassed
any clinical setting wherein patients with objectively measured car-
diac dysfunction seemed to require intravenous dopamine without
restrictions on dose or duration of administration. Cardiac dysfunc-
tion was defined as a left ventricular ejection fraction (LVEF) below
45% and/or a low cardiac output syndrome. Low cardiac output syn-
drome was defined as a pre‐existing or developing state of cardiac
insufficiency with underlying left‐ or right‐ventricular systolic dys-
function seemed to require inotrope support to maintain a systolic
blood pressure >90 mm Hg and a cardiac index >2.2 L·min−1·m−2.17
RCTs including both patients with and without cardiac dysfunction
were included in the review only if the majority (more than 50%) of
the included patients had cardiac dysfunction. During the selection
process, we had to exclude a substantial number of trials because
not all trials objectively measured cardiac dysfunction for each
patient. We realised that our eligibility criteria may not reflect all the
situations in which doctors decide to administer dopamine. To
increase the external validity of our systematic review, we con-
ducted a post hoc analysis including trials in which a substantial pro-
portion of patients (more than 25%) were assumed to have cardiac
dysfunction.
2.2 | Outcomes
The primary outcome was all‐cause mortality. The secondary out-
comes were serious adverse events (SAEs), myocardial infarction,
arrhythmias (including supra‐ and ventricular tachycardia and fibrilla-
tion), and renal failure requiring renal replacement therapy. SAEs
were defined according to the International Conference on Harmoni-
sation of Good Clinical Practice definitions, excluding mortality to
avoid double counts.18 Myocardial infarction, arrhythmias, and renal
replacement therapy were defined according to the criteria used in
the individual trials. We included data at longest follow‐up.
2.3 | Search methods
We used a sensitive search strategy that was likely to include all
clinical settings wherein cardiac dysfunction was prevalent: eg shock,
heart failure, cardiac surgery (Appendix S1). We searched the
Cochrane Central Register of Controlled Trials (CENTRAL), PubMed,
Web of Science, CINAHL, and Embase until 19 April 2018. We also
searched the World Health Association's (WHO's) trial platform, Clin-
icalTrials.gov, and FDA and EMA homepages for ongoing trials. Last,
we searched the references of the selected trials and previous meta‐
analyses to identify further relevant trials.
2.4 | Trial selection, data extraction, and bias risk
assessments
Two authors independently identified trials for inclusion and extracted
study, patient and intervention characteristics, evaluated outcomes,
and risks of bias according to the domains of bias in The Cochrane
Handbook for Systematic Reviews of Interventions.14 Trials with one
or more of the risks of bias domains classified at high or unclear risk
were considered trials at high risk of bias.14 The authors of the individ-
ual trials were contacted in case of any unclear or missing information.
Editorial Comment
This systematic review and meta‐analysis shows that the
evidence base for use of dopamine in critically ill adults
with cardiac dysfunction is sparse with no firm evidence for
benefit or harm. From this, routine use of dopamine in this
population does not seem justified in this patient group.
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All data on the outcomes of all trials were assessed for the
risks of systematic errors (‘bias’), the risks of other design errors,
and the risks of random errors. The three‐dimensional Manhattan
error matrix plot was used to facilitate the overview of available
evidence at a glance.19 We used a funnel plot to explore small
trial bias.14
2.5 | Statistical methods
Results were presented as relative risks (RR), odds ratios (OR), and Peto's
OR with 95% confidence interval (CI) when applicable. We used both a
fixed‐effect model and a random‐effects model for our meta‐analyses
and presented both models in case of discrepancy. Considering the
Records identified through
database searching
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(n = 46)
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Proportion with assumed
































F IGURE 1 PRISMA flow diagram. *All authors from the studies published since 1990 were contacted for additional data in case of missing
outcomes of interest [Colour figure can be viewed at wileyonlinelibrary.com]
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TABLE 1 Characteristics of the included trials
Trial, year N Dopamine dose Comparator(s) Cardiac function Outcomes
Acute heart failure
Kamiya24 24 Low dose:








Chen7 360 Low dose:
2.0 µg·kg−1·min−1
Placebo LVEF: 33% (IQR 22%‐50%)




Varriale25 20 Low dose:
2.0 µg·kg−1·min−1
Control Mean LVEF: 28.3% ± 9.1%
Depressed LV‐function
was an inclusion criterion
Mortality (in‐hospital)
Arrhythmias





Mean LVEF: 33% Mortality (30 d)
Serious adverse events
Arutiunov27 41 Low dose:
3.1 ± 0.2 µg·kg−1·min−1
Levosimendan (unknown
dose) + ivabradine 2dd 5 mg
Mean LVEF: 22%




Hsueh28 20 Moderate dose:
4.0 µg·kg−1·min−1
Dobutamine 4.0 µg·kg−1·min−1 LVEF: ±33% ± 10




Cotter29 20 Moderate dose:
(1) 4.0 + furosemide
2dd 40 mg
(2) 4.0 + furosemide
5 mg·kg−1




Giamouzis5 60 Moderate dose:
5.0 µg·kg−1·min−1
Furosemide 20 mg·h−1 LVEF: 36% ± 12%
Proportion LVEF <40%: 70%
Mortality (60 d)
Serious adverse events
Triposkiadis6 161 Moderate dose:
5.0 µg·kg−1·min−1
(1) Control
(2) Furosemide 20 mg·h−1
LVEF: 31% (25%‐45%)










CI 1.9 ± 0.7 L·min−1·m−2 Mortality (1 y)
Cardiac surgery
Sirivella31 100 Low dose:






Furosemide 1.4‐3 mg·kg−1 +
bumetadine 0.014 mg·kg−1
(other inotropes were given)
LVEF: 35%
Mean CO: 2.4 ± 0.2 L·min−1
Renal replacement therapy
Costa32 36 Low dose:
(1) 2.5 µg·kg−1·min−1
(2) 2.5 µg·kg−1·min−1 +
nitroprusside
Control Renal dysfunction was
attributable to severe HF in
all but three patients
Renal replacement therapy





(68% received other inotropes)
LVEF per group:
 Dopamine: 43% ± 16% Comparator: 44% ± 17%
Mortality (in‐hospital)
Renal replacement therapy
Rosseel34 70 Low dose:
3.1 ± 1.6 µg·kg−1·min−1
Dopexamine
1.2 ± 0.6 µg·kg−1·min−1
Low cardiac output syndrome
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anticipated clinical diversity, we emphasised the results from the ran-
dom‐effects model as it provides the most conservative estimate of
effect and/or CI. Heterogeneity was explored by inspection of forest
plots and the chi‐squared test with significance set at P‐value of 0.10,
and the quantity of heterogeneity was measured by I2.20
We used TSA on all outcomes to control for the risks of random
errors (“the play of chance”) and adjust the thresholds for statistical
significance when few data are present or when tested repeatedly,
comparable to interim analyses in a single RCT. TSA calculates a
diversity‐adjusted required information size (RIS) which compares
well to a sample size calculation for an RCT, and widens the thresh-
olds for statistical significance before the RIS is accrued. The RIS
was calculated based on an anticipated relative risk reduction (RRR)
of 10% and appropriately adjusted for heterogeneity in terms of
diversity (D2) according to an overall type‐I error of 5% and a power
of 90% considering early and repetitive testing.21 P‐values less than
TSA‐adjusted significance levels were considered statistically signifi-
cant.21 We explain the interpretation of a TSA‐graph in Figure S1.
The concepts of TSA are explained in detail in the TSA Manual
(http://www.ctu.dk/tsa) as well as in a recent overview.21 We used
the software package Review Manager 5.3.5 for the meta‐analyses
and the TSA program v.0.9.5.10 beta (http://www.ctu.dk/tsa) for the
TSA.
2.6 | Sensitivity and subgroup analyses
All outcomes were dichotomous. We constructed best‐worst and
worst‐best case scenarios as sensitivity analyses for participants lost
to follow‐up. Following our protocol, we conducted subgroup analy-
ses to explore clinical heterogeneity according to: (a) risk of bias in
trials; (b) control intervention (inactive compared to a potentially
active control); (c) trials assessing a low dose (<4 µg·kg−1·min−1)
compared to a moderate (4‐10 µg·kg−1·min−1) or high dose
(>10 µg·kg−1·min−1); (d) clinical setting (patients having cardiac sur-
gery compared to patients not having cardiac surgery).
2.7 | GRADE assessments
We used the Grading of Recommendations Assessment, Develop-
ment and Evaluations (GRADE) approach to rate and assess the qual-
ity of the body of evidence for each outcome and constructed a
“Summary of findings” table.22
3 | RESULTS
3.1 | Study selection
After screening the literature search, titles and abstracts, 341 articles
out of 10 858 hits remained (Figure 1). After assessment of full‐
texts, 86 studies were included in our systematic review. Additional
data was obtained from three studies.5,6,23 The main meta‐analysis
included 17 RCTs with in total 1218 patients.5‐7,24‐37 Two observa-
tional studies were assessed for harmful outcomes.23,38
3.2 | Characteristics of included trials
The characteristics of the 17 trials included in our meta‐analyses are
summarised in Table 1. In‐ and exclusion criteria of each trial are pre-
sented in Table S1. Nine trials had a two‐arm design, seven trials con-
sisted of three treatment arms, and one administered four different
treatments. One trial was placebo‐controlled,7 four trials used no
intervention in the control group,6,25,30,32 and 14 trials used a poten-
tially active control intervention: eight trials administered an inotropic
drug and six a diuretic drug. The administration duration of the study
drugs varied from only during the perioperative period up to a maxi-
mum of 5 days. Seven of the 17 trials included solely patients who all
TABLE 1 (Continued)
Trial, year N Dopamine dose Comparator(s) Cardiac function Outcomes








(2) Piroximone 3‐6 µg·kg−1·min−1
(43% received adrenaline)
A preoperative cardiac index
<2.5 L·min−1·m−2 was an
inclusion criterion
Mortality (6 ± 3 mo)
Myocardial infarction
Arrhythmias
Oppizzi36 26 Moderate dose:
5‐10 µg·kg−1·min−1
(15% crossed over)
Enoximone bolus 0.5 mg·kg−1,
followed by 5‐10 µg·kg−1·min−1
(5% crossed over)












(0% received other inotropes)
(2) Dobutamine 7‐14 µg·kg−1·min−1
(12% received other inotropes)
Cardiac index per group:
 Dopamine:
1.73 ± 0.08 L·min
−1·m−2
 Comparators:
1.83 ± 0.11 L·min
−1·m−2
Mortality (in‐hospital)
AHF, acute heart failure; LVEF, left‐ventricular ejection fraction.
Trials are sorted by setting and administered dose. We selected studies that provided data on cardiac function and accepted definitions of diagnoses
according to criteria used in each individual RCT.
aThe timing of administering the experimental intervention differed between the treatment arms.
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had objectively verified cardiac dysfunction defined by an LVEF below
45% or a low cardiac output syndrome.25,27,29,34,36,37 In a sensitivity
analyses we only included these seven trials; findings were comparable
to the analysis of 17 trials (e‐Table 2, Appendix S2).
3.3 | Risk of bias
All 17 trials were at overall high risk of bias (Figure 2). Fourteen tri-
als were at high risk of other bias, because nine trials (53%) did not
provide a statement on conflicts of interest, two trials (12%) allowed
cross‐over to another inotrope, and three trials (18%) were at risk of
vested interests.
3.4 | Outcomes
Table 2 summarises the meta‐analysed intervention effect estimates.
Due to absence of trials at overall low risk of bias and also due to
absence of trials administering high‐dose dopamine, we were unable to
conduct these predefined subgroup analyses. None of the comparisons
or outcomes could be analysed with the TSA using our prespecified
parameters. As a sensitivity analyses, we conducted a TSA with a type I
error of 5%, type II error of 10%, and an RRR of 20% on our primary out-
come mortality to evaluate the direction of the cumulative Z‐curve.
3.5 | Comparison 1: all critically ill patients with
cardiac dysfunction
3.5.1 | All‐cause mortality
All‐cause mortality was reported in 15 of the 17 trials with a total of
1038 included patients. One trial reported mortality only during their 72‐
hour study period, seven trials reported in‐hospital mortality, four trials
30‐ to 60‐day mortality, and three trials mortality after 6‐12 months of
follow‐up (Table 1). Dopamine did not statistically significantly affect
mortality when compared with any control intervention (60/457 [13%] vs
90/581 [15%]; RR 0.91; 95% CI 0.68‐1.21; I2 0%), or when compared
with an inactive control or with a potentially active control (Figure 3).
TSA on all trials showed that 19% of the RIS data was accrued and that
about another 4292 patients need to become randomised in RCTs before
the RIS will be reached (Figure 4; RR 0.91; TSA‐adjusted CI 0.50‐1.67).
3.5.2 | Serious adverse events
The occurrence of SAEs was reported in six trials with 582 included
patients. Dopamine was not statistically significantly associated with
SAEs when compared with any control intervention (62/268 [23%]
vs 51/314 [16%]; RR 1.20; 95% CI 0.91‐1.57; I2 2%; Figure 5). In a
sensitivity analysis, we included mortality in our SAEs and found no
statistically significant associations (122/457 [27%] vs 141/581
[24%]; RR 1.06; 95% CI 0.89‐1.27; I2 0%). TSA on all trials showed
that only 12% of the data was accrued and that about 4405 addi-
tional patients need to become randomised in RCTs before the RIS
will be reached (RR 1.20; TSA‐adjusted CI 0.41‐3.41; Figure S2).
F IGURE 2 Risk of bias assessment. Red, high risk; yellow, unclear
risk; green, low risk [Colour figure can be viewed at wileyonlinelibrary.
com]
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TABLE 2 Risk and odds ratios of all outcomes with subgroups analyses
Trialsa Patients Events RR or OR 95% CI Test for Interaction
Mortality 15 1038 150 0.91 0.68‐1.21 P = 1.00
(1) Placebo or control 5 452 84 0.90 0.61‐1.33
(1) Potentially active control 12 586 66 0.92 0.59‐1.43
(2) Low dose dopamine 7 568 68 0.84 0.54‐1.30
(2) Moderate dose dopamine 7 403 74 0.98 0.65‐1.47
(3) Acute heart failure 10 746 132 0.90 0.67‐1.23
(3) Cardiac surgery 5 292 18 0.93 0.35‐2.48
Serious adverse events 6 582 113 1.20 0.91‐1.57 P = 0.92
(1) Placebo or control 2 324 41 1.48 0.82‐2.67
(1) Potentially active control 5 258 72 1.34 0.75‐2.40
(2) Low dose dopamine 3 335 80 1.16 0.78‐1.71
(2) Moderate dose dopamine 3 267 33 1.70 0.86‐3.39
(3) Acute heart failure 4 486 59 1.54 0.94‐2.53
(3) Cardiac surgery 2 96 54 1.45 0.43‐4.90
Myocardial infarction 5 339 16 1.63 0.56‐4.71 P = 0.99
(1) Placebo or control 1 83 2 2.00 0.12‐33.2
(1) Potentially active control 5 256 14 1.57 0.50‐4.95
(2) Low dose dopamine 2 111 8 1.68 0.15‐18.8
(2) Moderate dose dopamine 3 228 8 1.99 0.47‐8.36
(3) Acute heart failure 2 202 7 2.91 0.55‐15.3
(3) Cardiac surgery 3 137 9 1.09 0.27‐4.33
Ventricular tachyarrhythmias 8 538 24 1.46 0.52‐4.10 P = 0.97
(1) Placebo or control 3 329 12 3.23 0.36‐28.6
(1) Potentially active control 6 209 12 0.94 0.28‐3.15
(2) Low dose dopamine 3 270 10 2.12 0.08‐55.3
(2) Moderate dose dopamine 5 268 14 1.09 0.35‐3.43
(3) Acute heart failure 6 471 21 1.29 0.38‐4.39
(3) Cardiac surgery 2 67 3 2.18 0.17‐27.6
Renal replacement therapy 4 371 51 0.44 0.07‐2.75 P = 0.94
(1) Placebo or control 2 113 1 0.64 0.03‐15.3
(1) Potentially active control 3 258 50 0.42 0.05‐3.67
(2) Low dose dopamine 3 210 48 0.26 0.02‐3.43
(2) Moderate dose dopamine 1 161 3 1.16 0.15‐9.15
(3) Acute heart failure 1 161 3 1.16 0.15‐9.15
(3) Cardiac surgery 3 210 48 0.26 0.02‐3.43
Atrial tachyarrhythmias 2 181 3 1.16 0.14‐9.65 P = 0.99
(1) Placebo or control 2 103 1 0.64 0.03‐16.2
(1) Potentially active control 1 78 2 1.81 0.11‐30.2
(2) Low dose dopamine 1 20 0 — —
(2) Moderate dose dopamine 1 161 3 1.16 0.14‐9.65
(3) Acute heart failure 2 181 3 1.16 0.14‐9.65
(3) Cardiac surgery 0 0 0 — —
RR, relative risk; OR, odds ratio; CI, confidence interval.
aSome trials compared dopamine with both a control intervention and a potentially active control (ie three‐arm design), which is why the combined
number of trials in subgroup analysis 1 differ from the total amount.
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3.5.3 | Other outcomes
There were no significant differences in favour of any intervention
on the other outcomes (Table 2). None of the outcomes could be
analysed with TSA using our prespecified parameters because <5%
of RIS was accrued.
3.6 | Comparison 2: trials subdivided by dopamine
dose (low compared to moderate)
3.6.1 | All‐cause mortality
Seven trials administered low‐dose dopamine (ie <4 µg·kg−1·min−1) and
seven trials a moderate dose (4‐10 µg·kg−1·min−1). Trials that studied
low‐dose dopamine in patients with heart‐failure targeted to increase
diuresis by improving renal perfusion, whereas low‐dose dopamine dur-
ing cardiac surgery was used to preserve renal function. Moderate dose‐
dopamine was administered in both patients with heart‐failure and
cardiac surgery patients to increase renal perfusion and ameliorate car-
diac function. One trial that reported mortality did not report on the
dopamine dose.30 No statistically significant associations between differ-
ent doses of dopamine and mortality were found (Table 2).
3.6.2 | Serious adverse events
The occurrence of SAEs was recorded in three trials that adminis-
tered low‐dose dopamine and in four trials administering moderate‐
dose dopamine. No significant differences were found for either
low‐ or moderate‐dose dopamine (Table 2).
3.6.3 | Other outcomes
In the low‐dose dopamine group there was significant heterogeneity
(I2 90%, P = 0.002) due to one trial reporting use of renal replace-
ment therapy in 36 of the 40 patients (90%) in the control group vs
2 of the 42 patients (5%) in the dopamine group. No significant
F IGURE 3 Forest plot of mortality in all trials stratified by intervention. Forest plot of all‐cause mortality in trials stratified by intervention.
Size of squares for risk ratio (RR) reflects the weight of the trial in the meta‐analysis. Horizontal bars are 95% confidence intervals (CI) [Colour
figure can be viewed at wileyonlinelibrary.com]
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differences were observed for any dose on any of the outcomes
(Table 2).
3.7 | Comparison 3: trials subdivided by setting
(heart failure compared to cardiac surgery)
3.7.1 | All‐cause mortality
Ten trials were conducted in patients admitted with acute heart fail-
ure and seven trials in patients undergoing cardiac surgery. Heart
failure was often based on clinical symptoms classified by the New
York Heart Association (NYHA) and a depressed LVEF (Table S1).
The type of cardiac surgery varied between the trials: two trials
included patients having cardiac artery bypass grafting,34,36 two trials
included patients having mitral valve surgery,35,37 and three trials
included patients having various cardiac surgeries.31‐33 Subgroup
analyses by clinical setting did not show any statistically significant
associations on mortality (Table 2).
3.7.2 | Serious adverse events
Serious adverse events were reported in four trials that included
patients with acute heart failure and in two trials that included
patients undergoing cardiac surgery. There were no statistically sig-
nificant associations on occurrence of SAEs in both settings (Table 2).
3.7.3 | Other outcomes
There was no significant difference in favour of any intervention on
the proportion of myocardial infarction, renal replacement therapy,
and ventricular or atrial tachyarrhythmias (Table 2).
3.8 | Post hoc meta‐analyses with broader inclusion
criteria of cardiac dysfunction
These post hoc meta‐analyses included trials in which a substantial
proportion of patients (>25%) were assumed to have cardiac dys-
function. This broader inclusion criterion added ten trials with
patients suffering from shock (n = 1679) or septic shock (n = 444),
who received high‐dose dopamine for treatment of hypotension.
This meta‐analysis included 40 trials with 4182 patients and full
details can be found in Appendix S2.
Dopamine seemed associated with increased mortality, increased
SAEs, and increased tachyarrhythmias when compared with a poten-























    • Mortality proportion control group: 15.3%
    • Relative risk reduction: 20%
    • Alpha: 5% (two-sided)
    • Bèta: 10%































    Diversity-adjusted required 
information size: 5330 patients
Z-curve
F IGURE 4 Trial Sequential Analysis for all‐cause mortality. The Trial Sequential Analysis is based on 15 trials, which is the meta‐analysed
effect of dopamine vs any (in)active comparator intervention. The blue cumulative z‐curve was constructed using a random‐effects model. The
horizontal green dotted lines represent the conventional naïve boundaries for benefit (positive) or harm (negative). The red dotted lines
represent the trial sequential boundaries for benefit (positive), harm (negative), or futility (middle triangular area) [Colour figure can be viewed
at wileyonlinelibrary.com]
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largely attributable to the trials which administered high‐dose dopa-
mine and accounted for 87% of weight in the pooled effect (Fig-
ure S3). All but one of these trials compared dopamine with
noradrenaline and two trials allowed other cardioactive co‐interven-
tions with dobutamine or open‐label noradrenaline. TSA including all
trials reporting on mortality showed that it is highly unlikely to show
a beneficial effect of dopamine with further trials, as the cumulative
Z‐curve would have to cross the futility area (Figure S4).
3.9 | Observational studies
One quasi‐randomised study and one observational study were
assessed for harms.23,38 One study compared dopamine to levosi-
mendan and recorded SAEs and arrhythmias38; the other evaluated
dopamine to an intra‐aortic balloon pump and reported myocardial
infarction and renal replacement therapy proportions.23 Dopamine
did not significantly affect any of these outcomes (Table S3).
3.10 | Quality of evidence
Based on GRADE, the certainty of the evidence on all outcomes was
judged as ‘very low’ and was mainly attributable to serious risks of
bias, serious indirectness, and very serious imprecision (Table 3). The
Manhattan error matrix plots showed that there are lacunas in the
evidence of dopamine regarding both systematic errors and random
errors (Figure S5). The funnel plots showed no clear arguments for
small trial bias including publication bias (Figure S6).
4 | DISCUSSION
Our main meta‐analysis consisting of 17 trials with 1218 patients did
not provide high‐quality evidence to support or refute the use of
dopamine. All trials were at overall high risk of bias, only one trial
compared dopamine with placebo, and TSA showed that further
thousands of patients need to be randomised before firm conclu-
sions can be drawn. The use of dopamine as preferred inotrope in
up to 25% of heart failure patients lacks evidence from RCTs.
The largest trial on dopamine thus far observed that high‐dose
dopamine, as compared with noradrenaline, is associated with increased
28‐day mortality in the subgroup of patients with cardiogenic shock.8
We could not include these patients in our main meta‐analysis because
cardiac function was not measured in each patient and the randomisa-
tion procedure was not stratified for the cardiogenic shock subgroup.
The increased mortality was supported by a meta‐analysis including tri-
als randomising patients with cardiogenic shock receiving high‐dose
dopamine.39 We were unable to include these trials because the meta‐
analysis did not elaborate on cardiac function of each trial population
and the full‐text manuscripts were inaccessible to us (ie the Wanfang
and Weipu Database). Based on these studies, high‐dose dopamine for
treatment of cardiogenic shock seems associated with increased harm.
Dopamine for treatment of cardiac dysfunction also seems harm-
ful according to observational data.11 Nevertheless, the quality of
current evidence on the possible benefits or harms of dopamine, mil-
rinone, levosimendan, and probably all other inotropes is considered
very low.40,41 There is currently no high‐quality evidence on which
F IGURE 5 Forest plot of serious adverse events in trials stratified by intervention. Forest plot of serious adverse events in all trials
stratified by intervention. Size of squares for risk ratio (RR) reflects the weight of the trial in the meta‐analysis. Horizontal bars are 95%
confidence intervals (CI) [Colour figure can be viewed at wileyonlinelibrary.com]
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inotrope should preferentially be administered to patients with car-
diac dysfunction.
Previous systematic reviews on dopamine in critically ill adult
patients differ in design; all studied dopamine in patients with car-
diogenic,39,42 hypotensive,9 or septic shock.43‐47 Some identified a
potentially harmful effect of dopamine on mortality and occurrence
of arrhythmias,39,43,44,46 while others were inconclusive.9,42,45,47
These systematic reviews used different inclusion criteria and most
studied high‐dose dopamine.9,39,43‐47 The main analysis of our sys-
tematic review included fewer patients (n = 1218) compared to five
of the other reviews (n = 510,39 n = 70,42 n = 1400,9 n = 2043,44
n = 1408,43,47 n = 3819,45 n = 171846) due to our more stringent
inclusion criteria on cardiac dysfunction. We selected patients with
objectively measured cardiac dysfunction because these patients
would presumably benefit the most from an inotropic drug based on
a pathophysiological reasoning. Critically ill patients with a normal
cardiac function probably benefit less from the inotropic effects of
dopamine and are more likely to only suffer potential harms.
4.1 | Limitations and strengths
Potential biases may have arisen during the review process. Our sys-
tematic review mainly included small trials (ie <100 patients per trial)
that used haemodynamic variables as their primary outcome. There-
fore, our effect estimates may contain covariate imbalances and the
included trials were individually underpowered for our outcomes.48
Such problems with imbalance and power are, however, best miti-
gated through the conduct of meta‐analyses.
It can be debated whether our inclusion criteria fully reflect daily
clinical practise. We were interested in patients with cardiac dys-
function based on cardiac index and LVEF measurements, which are
operator dependent and may have considerable interobserver vari-
ability.49,50 Though, these are currently the advocated measures to
quantify left‐ventricular function and often used as trigger to start
inotropic treatments.51
Although statistical heterogeneity was often absent, our meta‐
analyses had considerable clinical heterogeneity because (a) not all
trials included patients who all have objectively verified cardiac dys-
function and (b) dopamine was administered in different doses to
patients in different clinical settings, based on different assumed
pathophysiological mechanisms. In fact, very few of the included tri-
als had objective haemodynamic targets to direct infusion of dopa-
mine and other inotropes. We probably cannot move forward
understanding the role of inotropes before we understand the
pathophysiology of shock on organ level.
More insight is needed into the pathophysiology of shock on
organ level with bridging to haemodynamic goals to achieve optimal
organ function support in critically ill patients. To detect possible
sources of clinical heterogeneity, we first conducted subgroup analy-
ses on dopamine dose, clinical setting, and a sensitivity analysis of
trials exclusively including patients with cardiac dysfunction. Second,
we conducted post hoc meta‐analyses with a broader inclusion crite-
rion for cardiac dysfunction.
5 | CONCLUSIONS
Evidence for dopamine in critically ill adults with cardiac dysfunction
is sparse and of low quality due to high risks of systematic errors
and random errors. The use of dopamine in patients with cardiac
dysfunction can neither be recommended nor refuted.
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